Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX) has earned a consensus rating of “Moderate Buy” from the fourteen analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $12.9091.

Several equities research analysts have recently commented on the company. Raymond James Financial downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 28th. Canaccord Genuity Group cut their price objective on Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, April 28th. Craig Hallum assumed coverage on Compass Therapeutics in a report on Friday, February 13th. They issued a “buy” rating and a $15.00 price objective for the company. Citizens Jmp reissued a “market outperform” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Tuesday, April 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a report on Monday, April 20th.

Institutional Investors Weigh In On Compass Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Suvretta Capital Management LLC raised its stake in Compass Therapeutics by 0.6% in the 4th quarter. Suvretta Capital Management LLC now owns 14,182,379 shares of the company’s stock valued at $76,159,000 after acquiring an additional 81,220 shares during the period. Vivo Capital LLC raised its stake in Compass Therapeutics by 57.9% in the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after acquiring an additional 3,502,000 shares during the period. BVF Inc. IL raised its stake in Compass Therapeutics by 63.5% in the 4th quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock valued at $41,697,000 after acquiring an additional 3,014,842 shares during the period. Vanguard Group Inc. raised its stake in Compass Therapeutics by 45.6% in the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock valued at $24,720,000 after acquiring an additional 2,212,794 shares during the period. Finally, State Street Corp raised its stake in Compass Therapeutics by 57.4% in the 4th quarter. State Street Corp now owns 4,890,525 shares of the company’s stock valued at $26,262,000 after acquiring an additional 1,784,012 shares during the period. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Trading Down 4.2%

NASDAQ CMPX opened at $2.04 on Monday. The company has a market cap of $367.38 million, a PE ratio of -4.98 and a beta of 0.89. Compass Therapeutics has a 12 month low of $1.61 and a 12 month high of $6.88. The stock has a 50 day moving average of $3.49 and a 200-day moving average of $4.86.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10). As a group, sell-side analysts predict that Compass Therapeutics will post -0.42 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.